<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250410021712&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250410021712&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 10 Apr 2025 06:17:13 +0000</lastbuilddate>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Strengthening Temperature-Stroke Associations: Methodologic Considerations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1522. doi: 10.1016/j.jacc.2025.01.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204383</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.036>10.1016/j.jacc.2025.01.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204383</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Lingzhi Chu</dc:creator>
<dc:creator>Xiaomei Ma</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Strengthening Temperature-Stroke Associations: Methodologic Considerations</dc:title>
<dc:identifier>pmid:40204383</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.036</dc:identifier>
</item>
<item>
<title>Strengthening Temperature-Stroke Associations: Methodologic Considerations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1521. doi: 10.1016/j.jacc.2024.11.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204382</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.054>10.1016/j.jacc.2024.11.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204382</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Jian Huang</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Strengthening Temperature-Stroke Associations: Methodologic Considerations</dc:title>
<dc:identifier>pmid:40204382</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.054</dc:identifier>
</item>
<item>
<title>Articulating the JACC Journals' Direction in Times of Global Change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1515-1516. doi: 10.1016/j.jacc.2025.02.006. Epub 2025 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204381</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.006>10.1016/j.jacc.2025.02.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204381</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Biykem Bozkurt</dc:creator>
<dc:creator>Y Chandrashekhar</dc:creator>
<dc:creator>Bonnie Ky</dc:creator>
<dc:creator>Douglas L Mann</dc:creator>
<dc:creator>David J Moliterno</dc:creator>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:creator>Candice K Silversides</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Articulating the JACC Journals' Direction in Times of Global Change</dc:title>
<dc:identifier>pmid:40204381</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.006</dc:identifier>
</item>
<item>
<title>Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Is Enthusiasm Exceeding the Evidence?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1511-1514. doi: 10.1016/j.jacc.2025.03.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204380</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.002>10.1016/j.jacc.2025.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204380</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: Is Enthusiasm Exceeding the Evidence?</dc:title>
<dc:identifier>pmid:40204380</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.002</dc:identifier>
</item>
<item>
<title>One Step Closer to Unlocking Preeclampsia Prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1501-1503. doi: 10.1016/j.jacc.2025.03.455.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204379</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.455>10.1016/j.jacc.2025.03.455</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204379</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Christina M Ackerman-Banks</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Heather S Lipkind</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>One Step Closer to Unlocking Preeclampsia Prevention</dc:title>
<dc:identifier>pmid:40204379</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.455</dc:identifier>
</item>
<item>
<title>Genetic Risk and First-Trimester Cardiovascular Health Predict Hypertensive Disorders of Pregnancy in Nulliparous Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Lower genetic risk and higher first-trimester CVH were independently and additively associated with lower risk of developing HDPs in nulliparous individuals. Favorable CVH in early pregnancy may mitigate high genetic risk for HDP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1488-1500. doi: 10.1016/j.jacc.2025.02.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertensive disorders of pregnancy (HDPs) (preeclampsia/eclampsia and gestational hypertension) are a leading cause of maternal and perinatal morbidity and mortality and are associated with long-term maternal cardiovascular disease. High genetic risk and poor cardiovascular health (CVH) are each associated with HDPs, but whether genetic risk for HDP is modified by CVH status in early pregnancy is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, the authors sought to test the independent and joint associations of genetic risk and first-trimester CVH with development of HDP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined genotyped participants from the nuMoM2b (Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be), a prospective observational cohort that enrolled nulliparous individuals with singleton pregnancies from 2010 to 2013 at 8 U.S. clinical sites. Genetic risk was calculated according to a validated genetic risk score for HDP. A first-trimester CVH score was closely adapted from the American Heart Association Life's Essential 8 model. Genetic risk and CVH were each categorized as low (bottom quintile), intermediate (quintile 2-4), or high (top quintile). The primary outcome was development of HDP. Multivariable-adjusted logistic regression was used to test the independent and joint associations of genetic risk and CVH with development of HDPs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 7,499 participants (mean age 27.0 years), the median first-trimester CVH score was 77.1 (Q1-Q3: 67.1-85.7). Overall, 1,032 participants (13.8%) developed an HDP (487 [6.5%] preeclampsia, 545 [7.3%] gestational hypertension). Genetic risk and CVH were each independently and additively associated with HDP (high vs low genetic risk: adjusted OR [aOR]: 2.21 [95% CI: 1.78-2.77; P &lt; 0.001]; low vs high CVH: aOR: 2.92 [95% CI: 2.28-3.74; P &lt; 0.001]). There was no significant interaction between genetic risk and CVH regarding risk of HDPs (P<sub>interaction</sub> >; 0.05). HDP incidence ranged from 4.5% (low genetic risk, high CVH) to 25.7% (high genetic risk, low CVH). Compared with low CVH, high CVH was associated with 53%-74% lower risk of HDP across genetic risk strata. Findings were consistent when examining preeclampsia/eclampsia and gestational hypertension separately.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Lower genetic risk and higher first-trimester CVH were independently and additively associated with lower risk of developing HDPs in nulliparous individuals. Favorable CVH in early pregnancy may mitigate high genetic risk for HDP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204378</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.015>10.1016/j.jacc.2025.02.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204378</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Vineetha Mathew</dc:creator>
<dc:creator>Raiyan R Khan</dc:creator>
<dc:creator>Amanda R Jowell</dc:creator>
<dc:creator>Qi Yan</dc:creator>
<dc:creator>Itsik Pe'er</dc:creator>
<dc:creator>Buu Truong</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Lynn M Yee</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Garima Sharma</dc:creator>
<dc:creator>Aniruddh P Patel</dc:creator>
<dc:creator>So Mi Jemma Cho</dc:creator>
<dc:creator>Maria A Pabon</dc:creator>
<dc:creator>Rebecca B McNeil</dc:creator>
<dc:creator>Jillyn Spencer</dc:creator>
<dc:creator>Robert M Silver</dc:creator>
<dc:creator>Lisa D Levine</dc:creator>
<dc:creator>William A Grobman</dc:creator>
<dc:creator>Janet M Catov</dc:creator>
<dc:creator>David M Haas</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Risk and First-Trimester Cardiovascular Health Predict Hypertensive Disorders of Pregnancy in Nulliparous Women</dc:title>
<dc:identifier>pmid:40204378</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.015</dc:identifier>
</item>
<item>
<title>Troponin Testing for Cardiovascular Primary Prevention Decision Making?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1485-1487. doi: 10.1016/j.jacc.2025.02.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204377</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.026>10.1016/j.jacc.2025.02.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204377</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Cian P McCarthy</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Troponin Testing for Cardiovascular Primary Prevention Decision Making?</dc:title>
<dc:identifier>pmid:40204377</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.026</dc:identifier>
</item>
<item>
<title>Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40204376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 15;85(14):1471-1484. doi: 10.1016/j.jacc.2025.02.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The extent to which high-sensitivity cardiac troponin can predict cardiovascular disease (CVD) is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We aimed to quantify the potential advantage of adding information on cardiac troponins to conventional risk factors in the prevention of CVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We meta-analyzed individual-participant data from 15 cohorts, comprising 62,150 participants without prior CVD. We calculated HRs, measures of risk discrimination, and reclassification after adding cardiac troponin T (cTnT) or I (cTnI) to conventional risk factors. The primary outcome was first-onset CVD (ie, coronary heart disease or stroke). We then modeled the implications of initiating statin therapy using incidence rates from 2.1 million individuals from the United Kingdom.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among participants with cTnT or cTnI measurements, 8,133 and 3,749 incident CVD events occurred during a median follow-up of 11.8 and 9.8 years, respectively. HRs for CVD per 1-SD higher concentration were 1.31 (95% CI: 1.25-1.37) for cTnT and 1.26 (95% CI: 1.19-1.33) for cTnI. Addition of cTnT or cTnI to conventional risk factors was associated with C-index increases of 0.015 (95% CI: 0.012-0.018) and 0.012 (95% CI: 0.009-0.015) and continuous net reclassification improvements of 6% and 5% in cases and 22% and 17% in noncases. One additional CVD event would be prevented for every 408 and 473 individuals screened based on statin therapy in those whose CVD risk is reclassified from intermediate to high risk after cTnT or cTnI measurement, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40204376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40204376</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.016>10.1016/j.jacc.2025.02.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40204376</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Anoop S V Shah</dc:creator>
<dc:creator>Spencer J Keene</dc:creator>
<dc:creator>Lisa Pennells</dc:creator>
<dc:creator>Stephen Kaptoge</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:creator>Matthew Walker</dc:creator>
<dc:creator>Julianne D Halley</dc:creator>
<dc:creator>Sara Rocha</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Vilmundur Gudnason</dc:creator>
<dc:creator>Stephan J L Bakker</dc:creator>
<dc:creator>Sasiwarang G Wannamethee</dc:creator>
<dc:creator>Manan Pareek</dc:creator>
<dc:creator>Kai M Eggers</dc:creator>
<dc:creator>J Wouter Jukema</dc:creator>
<dc:creator>Graeme J Hankey</dc:creator>
<dc:creator>James A deLemos</dc:creator>
<dc:creator>Ian Ford</dc:creator>
<dc:creator>Torbjørn Omland</dc:creator>
<dc:creator>Magnus Nakrem Lyngbakken</dc:creator>
<dc:creator>Bruce M Psaty</dc:creator>
<dc:creator>Christopher R deFilippi</dc:creator>
<dc:creator>Angela M Wood</dc:creator>
<dc:creator>John Danesh</dc:creator>
<dc:creator>Paul Welsh</dc:creator>
<dc:creator>Naveed Sattar</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Emanuele Di Angelantonio</dc:creator>
<dc:creator>CAPRICE Co-Investigators</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis</dc:title>
<dc:identifier>pmid:40204376</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.016</dc:identifier>
</item>
<item>
<title>Fast, accurate, and versatile data analysis platform for the quantification of molecular spatiotemporal signals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40203826/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>Optical recording of intricate molecular dynamics is becoming an indispensable technique for biological studies, accelerated by the development of new or improved biosensors and microscopy technology. This creates major computational challenges to extract and quantify biologically meaningful spatiotemporal patterns embedded within complex and rich data sources, many of which cannot be captured with existing methods. Here, we introduce activity quantification and analysis (AQuA2), a fast,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 4:S0092-8674(25)00285-5. doi: 10.1016/j.cell.2025.03.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Optical recording of intricate molecular dynamics is becoming an indispensable technique for biological studies, accelerated by the development of new or improved biosensors and microscopy technology. This creates major computational challenges to extract and quantify biologically meaningful spatiotemporal patterns embedded within complex and rich data sources, many of which cannot be captured with existing methods. Here, we introduce activity quantification and analysis (AQuA2), a fast, accurate, and versatile data analysis platform built upon advanced machine-learning techniques. It decomposes complex live-imaging-based datasets into elementary signaling events, allowing accurate and unbiased quantification of molecular activities and identification of consensus functional units. We demonstrate applications across a wide range of biosensors, cell types, organs, animal models, microscopy techniques, and imaging approaches. As exemplar findings, we show how AQuA2 identified drug-dependent interactions between neurons and astroglia, as well as distinct sensorimotor signal propagation patterns in the mouse spinal cord.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40203826/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40203826</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.012>10.1016/j.cell.2025.03.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40203826</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xuelong Mi</dc:creator>
<dc:creator>Alex Bo-Yuan Chen</dc:creator>
<dc:creator>Daniela Duarte</dc:creator>
<dc:creator>Erin Carey</dc:creator>
<dc:creator>Charlotte R Taylor</dc:creator>
<dc:creator>Philipp N Braaker</dc:creator>
<dc:creator>Mark Bright</dc:creator>
<dc:creator>Rafael G Almeida</dc:creator>
<dc:creator>Jing-Xuan Lim</dc:creator>
<dc:creator>Virginia M S Ruetten</dc:creator>
<dc:creator>Yizhi Wang</dc:creator>
<dc:creator>Mengfan Wang</dc:creator>
<dc:creator>Weizhan Zhang</dc:creator>
<dc:creator>Wei Zheng</dc:creator>
<dc:creator>Michael E Reitman</dc:creator>
<dc:creator>Yongkang Huang</dc:creator>
<dc:creator>Xiaoyu Wang</dc:creator>
<dc:creator>Lei Li</dc:creator>
<dc:creator>HanFei Deng</dc:creator>
<dc:creator>Song-Hai Shi</dc:creator>
<dc:creator>Kira E Poskanzer</dc:creator>
<dc:creator>David A Lyons</dc:creator>
<dc:creator>Axel Nimmerjahn</dc:creator>
<dc:creator>Misha B Ahrens</dc:creator>
<dc:creator>Guoqiang Yu</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Fast, accurate, and versatile data analysis platform for the quantification of molecular spatiotemporal signals</dc:title>
<dc:identifier>pmid:40203826</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.012</dc:identifier>
</item>
<item>
<title>Quiescent cell re-entry is limited by macroautophagy-induced lysosomal damage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40203825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>To maintain tissue homeostasis, many cells reside in a quiescent state until prompted to divide. The reactivation of quiescent cells is perturbed with aging and may underlie declining tissue homeostasis and resiliency. The unfolded protein response regulators IRE-1 and XBP-1 are required for the reactivation of quiescent cells in developmentally L1-arrested C. elegans. Utilizing a forward genetic screen in C. elegans, we discovered that macroautophagy targets protein aggregates to lysosomes in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 4:S0092-8674(25)00282-X. doi: 10.1016/j.cell.2025.03.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">To maintain tissue homeostasis, many cells reside in a quiescent state until prompted to divide. The reactivation of quiescent cells is perturbed with aging and may underlie declining tissue homeostasis and resiliency. The unfolded protein response regulators IRE-1 and XBP-1 are required for the reactivation of quiescent cells in developmentally L1-arrested C. elegans. Utilizing a forward genetic screen in C. elegans, we discovered that macroautophagy targets protein aggregates to lysosomes in quiescent cells, leading to lysosome damage. Genetic inhibition of macroautophagy and stimulation of lysosomes via the overexpression of HLH-30 (TFEB/TFE3) synergistically reduces lysosome damage. Damaged lysosomes require IRE-1/XBP-1 for their repair following prolonged L1 arrest. Protein aggregates are also targeted to lysosomes by macroautophagy in quiescent cultured mammalian cells and are associated with lysosome damage. Thus, lysosome damage is a hallmark of quiescent cells, and limiting lysosome damage by restraining macroautophagy can stimulate their reactivation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40203825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40203825</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.009>10.1016/j.cell.2025.03.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40203825</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Andrew Murley</dc:creator>
<dc:creator>Ann Catherine Popovici</dc:creator>
<dc:creator>Xiwen Sophie Hu</dc:creator>
<dc:creator>Anina Lund</dc:creator>
<dc:creator>Kevin Wickham</dc:creator>
<dc:creator>Jenni Durieux</dc:creator>
<dc:creator>Larry Joe</dc:creator>
<dc:creator>Etai Koronyo</dc:creator>
<dc:creator>Hanlin Zhang</dc:creator>
<dc:creator>Naomi R Genuth</dc:creator>
<dc:creator>Andrew Dillin</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Quiescent cell re-entry is limited by macroautophagy-induced lysosomal damage</dc:title>
<dc:identifier>pmid:40203825</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.009</dc:identifier>
</item>
<item>
<title>Human proteome distribution atlas for tissue-specific plasma proteome dynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40203824/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>The plasma proteome is maintained by the influx and efflux of proteins from surrounding organs and cells. To quantify the extent to which different organs and cells impact the plasma proteome in healthy and diseased conditions, we developed a mass-spectrometry-based proteomics strategy to infer the tissue origin of proteins detected in human plasma. We first constructed an extensive human proteome atlas from 18 vascularized organs and the 8 most abundant cell types in blood. The atlas was...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 4:S0092-8674(25)00286-7. doi: 10.1016/j.cell.2025.03.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The plasma proteome is maintained by the influx and efflux of proteins from surrounding organs and cells. To quantify the extent to which different organs and cells impact the plasma proteome in healthy and diseased conditions, we developed a mass-spectrometry-based proteomics strategy to infer the tissue origin of proteins detected in human plasma. We first constructed an extensive human proteome atlas from 18 vascularized organs and the 8 most abundant cell types in blood. The atlas was interfaced with previous RNA and protein atlases to objectively define proteome-wide protein-organ associations to infer the origin and enable the reproducible quantification of organ-specific proteins in plasma. We demonstrate that the resource can determine disease-specific quantitative changes of organ-enriched protein panels in six separate patient cohorts, including sepsis, pancreatitis, and myocardial injury. The strategy can be extended to other diseases to advance our understanding of the processes contributing to plasma proteome dynamics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40203824/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40203824</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.013>10.1016/j.cell.2025.03.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40203824</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Erik Malmström</dc:creator>
<dc:creator>Lars Malmström</dc:creator>
<dc:creator>Simon Hauri</dc:creator>
<dc:creator>Tirthankar Mohanty</dc:creator>
<dc:creator>Aaron Scott</dc:creator>
<dc:creator>Christofer Karlsson</dc:creator>
<dc:creator>Carlos Gueto-Tettay</dc:creator>
<dc:creator>Emma Åhrman</dc:creator>
<dc:creator>Shahab Nozohoor</dc:creator>
<dc:creator>Bobby Tingstedt</dc:creator>
<dc:creator>Sara Regner</dc:creator>
<dc:creator>Peter Elfving</dc:creator>
<dc:creator>Leif Bjermer</dc:creator>
<dc:creator>Andreas Forsvall</dc:creator>
<dc:creator>Alexander Doyle</dc:creator>
<dc:creator>Mattias Magnusson</dc:creator>
<dc:creator>Ingrid Hedenfalk</dc:creator>
<dc:creator>Päivi Kannisto</dc:creator>
<dc:creator>Christian Brandt</dc:creator>
<dc:creator>Emma Nilsson</dc:creator>
<dc:creator>Lars B Dahlin</dc:creator>
<dc:creator>Johan Malm</dc:creator>
<dc:creator>Adam Linder</dc:creator>
<dc:creator>Emma Niméus</dc:creator>
<dc:creator>Johan Malmström</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Human proteome distribution atlas for tissue-specific plasma proteome dynamics</dc:title>
<dc:identifier>pmid:40203824</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.013</dc:identifier>
</item>
<item>
<title>Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40203823/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>Skeletal muscle contraction is triggered by acetylcholine (ACh) binding to its ionotropic receptors (AChRs) at neuromuscular junctions. In myasthenia gravis (MG), autoantibodies target AChRs, disrupting neurotransmission and causing muscle weakness. While treatments exist, variable patient responses suggest pathogenic heterogeneity. Progress in understanding the molecular basis of MG has been limited by the absence of structures of intact human muscle AChRs. Here, we present high-resolution...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 2:S0092-8674(25)00277-6. doi: 10.1016/j.cell.2025.03.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Skeletal muscle contraction is triggered by acetylcholine (ACh) binding to its ionotropic receptors (AChRs) at neuromuscular junctions. In myasthenia gravis (MG), autoantibodies target AChRs, disrupting neurotransmission and causing muscle weakness. While treatments exist, variable patient responses suggest pathogenic heterogeneity. Progress in understanding the molecular basis of MG has been limited by the absence of structures of intact human muscle AChRs. Here, we present high-resolution cryoelectron microscopy (cryo-EM) structures of the human adult AChR in different functional states. Using six MG patient-derived monoclonal antibodies, we mapped distinct epitopes involved in diverse pathogenic mechanisms, including receptor blockade, internalization, and complement activation. Electrophysiological and binding assays revealed how these autoantibodies directly inhibit AChR channel activation. These findings provide critical insights into MG immunopathogenesis, uncovering unrecognized antibody epitope diversity and modes of receptor inhibition, and provide a framework for developing personalized therapies targeting antibody-mediated autoimmune disorders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40203823/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40203823</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.004>10.1016/j.cell.2025.03.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40203823</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Huanhuan Li</dc:creator>
<dc:creator>Minh C Pham</dc:creator>
<dc:creator>Jinfeng Teng</dc:creator>
<dc:creator>Kevin C O'Connor</dc:creator>
<dc:creator>Colleen M Noviello</dc:creator>
<dc:creator>Ryan E Hibbs</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures</dc:title>
<dc:identifier>pmid:40203823</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.004</dc:identifier>
</item>
<item>
<title>Management of de novo heart failure with reduced ejection fraction: guideline-recommended medical therapy comes first</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 9:ehaf157. doi: 10.1093/eurheartj/ehaf157. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202856</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf157>10.1093/eurheartj/ehaf157</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202856</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Christian Veltmann</dc:creator>
<dc:creator>David Duncker</dc:creator>
<dc:creator>Lars Siegfried Maier</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Management of de novo heart failure with reduced ejection fraction: guideline-recommended medical therapy comes first</dc:title>
<dc:identifier>pmid:40202856</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf157</dc:identifier>
</item>
<item>
<title>Multimodal approaches for targeted treatment of heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 9:ehaf156. doi: 10.1093/eurheartj/ehaf156. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202849</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf156>10.1093/eurheartj/ehaf156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202849</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Ibrahim Akin</dc:creator>
<dc:creator>Nazha Hamdani</dc:creator>
<dc:creator>Ibrahim El-Battrawy</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multimodal approaches for targeted treatment of heart failure</dc:title>
<dc:identifier>pmid:40202849</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf156</dc:identifier>
</item>
<item>
<title>Error in End Matter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 1;10(4):402. doi: 10.1001/jamacardio.2025.0703.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202757</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0703>10.1001/jamacardio.2025.0703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202757</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:date>2025-04-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in End Matter</dc:title>
<dc:identifier>pmid:40202757</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0703</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 1;10(4):304. doi: 10.1001/jamacardio.2024.3417.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202756</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3417>10.1001/jamacardio.2024.3417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202756</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:date>2025-04-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:40202756</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3417</dc:identifier>
</item>
<item>
<title>Progressive Kidney Dysfunction After Left Atrial Appendage Closure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 9. doi: 10.1001/jamacardio.2025.0258. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202743</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0258>10.1001/jamacardio.2025.0258</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202743</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Shuaishuai Yuan</dc:creator>
<dc:creator>Chao Tao</dc:creator>
<dc:creator>Peijun Li</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Progressive Kidney Dysfunction After Left Atrial Appendage Closure</dc:title>
<dc:identifier>pmid:40202743</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0258</dc:identifier>
</item>
<item>
<title>Self-Administered Etripamil and Emergency Department Visits in Supraventricular Tachycardia: A Secondary Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Apr 9. doi: 10.1001/jamacardio.2025.0417. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202738</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0417>10.1001/jamacardio.2025.0417</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202738</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Sean D Pokorney</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Paul Dorian</dc:creator>
<dc:creator>James E Ip</dc:creator>
<dc:creator>Bruce S Stambler</dc:creator>
<dc:creator>David B Bharucha</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Self-Administered Etripamil and Emergency Department Visits in Supraventricular Tachycardia: A Secondary Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40202738</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0417</dc:identifier>
</item>
<item>
<title>Risks of Safety Mode in Recalled Boston Scientific Pacemakers: Implications for Pacemaker-Dependent Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 4:S0735-1097(25)06055-3. doi: 10.1016/j.jacc.2025.03.525. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202464</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.525>10.1016/j.jacc.2025.03.525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202464</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Pranav Mankad</dc:creator>
<dc:creator>Kenneth Ellenbogen</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risks of Safety Mode in Recalled Boston Scientific Pacemakers: Implications for Pacemaker-Dependent Patients</dc:title>
<dc:identifier>pmid:40202464</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.525</dc:identifier>
</item>
<item>
<title>Complications Associated With Safety Mode Initiation in Recalled Boston Scientific Pacemakers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202463/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 5:S0735-1097(25)05926-1. doi: 10.1016/j.jacc.2025.03.501. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202463/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202463</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.501>10.1016/j.jacc.2025.03.501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202463</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Hope Caughron</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:creator>Merritt H Raitt</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Complications Associated With Safety Mode Initiation in Recalled Boston Scientific Pacemakers</dc:title>
<dc:identifier>pmid:40202463</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.501</dc:identifier>
</item>
<item>
<title>Improving Medical Device Safety Surveillance: Bridging Capability and Commitment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40202462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250410021712&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 7:S0735-1097(25)06054-1. doi: 10.1016/j.jacc.2025.03.524. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40202462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250410021712&v=2.18.0.post9+e462414">40202462</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.524>10.1016/j.jacc.2025.03.524</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40202462</guid>
<pubDate>Wed, 09 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Lesley H Curtis</dc:creator>
<dc:creator>Robert M Califf</dc:creator>
<dc:date>2025-04-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Improving Medical Device Safety Surveillance: Bridging Capability and Commitment</dc:title>
<dc:identifier>pmid:40202462</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.524</dc:identifier>
</item>





























</channel>
</rss>